Results 221 to 230 of about 15,854,076 (410)
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
Life Style and Urinary 8‐Hydroxydeoxyguanosine, a Marker of Oxidative DNA Damage: Effects of Exercise, Working Conditions, Meat Intake, Body Mass Index, and Smoking [PDF]
Hiroshi Kasai+6 more
openalex +1 more source
Employment Responses to a Partner's Disability Onset ("Care Shocks"): Do Working Conditions Matter? [PDF]
Beaufils C, Baumberg Geiger B, Glaser K.
europepmc +1 more source
Have a nice day! The American journey to better working conditions [PDF]
Employment (Economic theory ...
Richard Alm, W. Michael Cox
core
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald+18 more
wiley +1 more source
Working Conditions, Musculoskeletal Pain and Wellbeing Among Hospital Surgeons: A Cross-Sectional Study. [PDF]
Ntani G+6 more
europepmc +1 more source
Comparative analysis of working conditions in the European Union Member States [PDF]
This paper presents the main findings of the author’s study of statistics as well as Eu-ropean surveys on working conditions. Such solutions enabled to compare the data and make the results more reliable.
Wach, Krzysztof
core +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias+12 more
wiley +1 more source